ASCO26: RevMed’s daraxonrasib presents a turning point for pancreatic cancer - Clinical Trials Arena

ASCO26: RevMed’s daraxonrasib presents a turning point for pancreatic cancer  Clinical Trials ArenaDaily pill doubles survival time for pancreatic cancer patients  BBC‘Landmark’ pancreatic cancer drug keeps patients alive for twice as long  The Washington PostDaily pill can double survival time for world’s deadliest cancer, trial shows | Pancreas cancer  The GuardianStanding ovation at ASCO 2026: Daraxonrasib Shines in Pancreatic Cancer Breakthrough  Medical Dialogues